About PRODIGY BIOTECH, INC.
ProdIgY Biotech is pioneering IgY-based antibody therapeutics to revolutionize the treatment of liver diseases through microbiome modulation, focusing on alcohol-associated hepatitis (AH) by targeting the gut-liver axis.
Development of IgY-based antibody therapeuticsMicrobiome modulation for liver disease treatmentSelective neutralization of harmful microbial componentsNon-invasive therapies targeting the gut-liver axisPreclinical and clinical development of therapies for alcohol-associated hepatitis (AH)
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to PRODIGY BIOTECH, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.